Alterity Therapeutics presents analyses related to OH from ATH434-201 trial

Alterity Therapeutics (ATHE) announced that analyses on the baseline characteristics related to orthostatic hypotension, OH, from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy, MSA, were featured in an oral presentation at the American Autonomic Society, AAS, 36th International Symposium on the Autonomic Nervous System that took place in Clearwater Beach, Florida, USA. The oral platform presentation provided a review of the ATH434-201 trial results with an emphasis on the baseline characteristics and analyses related to orthostatic hypotension. In the trial, severe OH is defined as a sustained decrease in systolic blood pressure greater than 30mm Hg after three minutes of standing. Baseline data from the trial revealed that severe OH was substantially higher in the 75 mg dose group at 29.2% of participants, versus 4% in the 50 mg arm and 4.5% in the placebo arm. When orthostatic blood pressure change was used as a covariate in the analysis of the UMSARS I1 at 52 weeks, the efficacy signal in 75 mg dose group strengthened from -2.4 to -2.8 points, improving the relative treatment effect from 30% to 35%.